Listen: With Genzyme, FDA Is ‘Sending A Signal’



Embed Code

Copy/paste the following code


After nearly a year of production struggles, Cambridge-based Genzyme is facing growing pressure from shareholders and customers to catch up with demand for drugs to treat some rare genetic disorders. Genzyme is expecting federal regulators to levy a fine of at least $175 million for quality control problems at its manufacturing facility in Allston. The plant is back in operation, but Genzyme says it needs more time to get all of the needed medications out.

Gary Pisano, a professor of business administration at Harvard Business School, joined WBUR Friday morning to talk about quality control and the impact it could have at Genzyme.

Please follow our community rules when engaging in comment discussion on this site.